search
Back to results

TriVascular European Union (EU) Abdominal Stent Graft Trial

Primary Purpose

Abdominal Aortic Aneurysm

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Implant of Ovation Abdominal Stent Graft System
Sponsored by
TriVascular, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Aortic Aneurysm focused on measuring abdominal, aortic, aneurysm

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is > 18 years of age
  2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
  3. Patient has signed an Ethics Committee (EC) approved Informed Consent Form
  4. Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification; refer to Appendix III: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
  5. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:

    • Abdominal aortic aneurysm ≥5.0 cm in diameter
    • Aneurysm has increased in size by 0.5 cm in last 6 months.
    • Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
  6. Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular AAA device.
  7. Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium.
  8. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
  9. Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm.
  10. Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm.
  11. Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm.
  12. Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is <10 mm.
  13. Patient must be willing to comply with all required follow-up exams.

Exclusion Criteria:

  1. Patient has a dissecting aneurysm
  2. Patient has an acutely ruptured aneurysm
  3. Patient has an acute vascular injury
  4. Patient has a need for emergent surgery
  5. Patient has a known thoracic aortic aneurysm or dissection.
  6. Patient has a mycotic aneurysm or has an active systemic infection
  7. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
  8. Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months.
  9. Patient has a major surgical or interventional procedure planned ≤30 days of the AAA repair.
  10. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
  11. Patient has history of bleeding disorders or refuses blood transfusions.
  12. Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl
  13. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
  14. Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers or nitinol.
  15. Patient has a body habitus that would inhibit X-ray visualization of the aorta
  16. Patient has a limited life expectancy of less than 1 year
  17. Patient is currently participating in another investigational device or drug clinical trial
  18. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Sites / Locations

  • Herz- und Gefässzentrum Bad Bevensen
  • Klinikum Dortmund GmbH
  • Cardiovascular Center Frankfurt-Sankt Katherinen
  • Universitäres Herz und Gefäß Zentrum Hamburg
  • Univeristy Klinik Köln
  • Herzzentrum Leipzig
  • St Franziskus Hospital Munster

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Ovation Abdominal Stent Graft System

Arm Description

Implant of Ovation Abdominal Stent Graft System

Outcomes

Primary Outcome Measures

The primary safety endpoint is defined as the proportion of subjects who experience a Serious Adverse Event within 30 days of the initial procedure.
The safety of the TriVascular AAA Stent Graft will be determined by comparing the rate of Serious Adverse Events in the Treatment Group against the rate of Serious Adverse Events in the Control Group within 30 days of the initial procedure.

Secondary Outcome Measures

To evaluate the performance of the TriVascular AAA Stent-Graft System within 30 days of the initial procedure.
The performance of the TriVascular AAA Stent-Graft System will be determined by comparing the composite success rate in the Treatment Group against an estimated success rate of 80% in the Control Group within 30 days of the initial procedure. The composite success rate is defined as: Technical Success, defined as successful delivery and deployment of one aortic body and two iliac limbs. Absence of Type I and III endoleaks Absence of Rupture Absence of Conversion to Open Surgical Repair Freedom from mortality

Full Information

First Posted
March 31, 2010
Last Updated
June 3, 2021
Sponsor
TriVascular, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01097772
Brief Title
TriVascular European Union (EU) Abdominal Stent Graft Trial
Official Title
A Clinical Study to Evaluate the Safety and Performance of the TriVascular Ovation™ Abdominal Stent Graft System
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
March 2010 (Actual)
Primary Completion Date
October 29, 2010 (Actual)
Study Completion Date
September 16, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TriVascular, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Clinical Study to Evaluate the Safety and Performance of the TriVascular Ovation Abdominal Stent Graft System
Detailed Description
A prospective, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and performance of the TriVascular AAA Stent Graft when used in the treatment of patients with Abdominal Aortic Aneurysms (AAA).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysm
Keywords
abdominal, aortic, aneurysm

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ovation Abdominal Stent Graft System
Arm Type
Other
Arm Description
Implant of Ovation Abdominal Stent Graft System
Intervention Type
Device
Intervention Name(s)
Implant of Ovation Abdominal Stent Graft System
Intervention Description
Single occurrence permanent implant of AAA device.
Primary Outcome Measure Information:
Title
The primary safety endpoint is defined as the proportion of subjects who experience a Serious Adverse Event within 30 days of the initial procedure.
Description
The safety of the TriVascular AAA Stent Graft will be determined by comparing the rate of Serious Adverse Events in the Treatment Group against the rate of Serious Adverse Events in the Control Group within 30 days of the initial procedure.
Time Frame
30-Days
Secondary Outcome Measure Information:
Title
To evaluate the performance of the TriVascular AAA Stent-Graft System within 30 days of the initial procedure.
Description
The performance of the TriVascular AAA Stent-Graft System will be determined by comparing the composite success rate in the Treatment Group against an estimated success rate of 80% in the Control Group within 30 days of the initial procedure. The composite success rate is defined as: Technical Success, defined as successful delivery and deployment of one aortic body and two iliac limbs. Absence of Type I and III endoleaks Absence of Rupture Absence of Conversion to Open Surgical Repair Freedom from mortality
Time Frame
30-Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is > 18 years of age Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study) Patient has signed an Ethics Committee (EC) approved Informed Consent Form Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification; refer to Appendix III: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following: Abdominal aortic aneurysm ≥5.0 cm in diameter Aneurysm has increased in size by 0.5 cm in last 6 months. Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular AAA device. Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery. Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm. Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm. Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm. Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is <10 mm. Patient must be willing to comply with all required follow-up exams. Exclusion Criteria: Patient has a dissecting aneurysm Patient has an acutely ruptured aneurysm Patient has an acute vascular injury Patient has a need for emergent surgery Patient has a known thoracic aortic aneurysm or dissection. Patient has a mycotic aneurysm or has an active systemic infection Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina) Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months. Patient has a major surgical or interventional procedure planned ≤30 days of the AAA repair. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome). Patient has history of bleeding disorders or refuses blood transfusions. Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment. Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers or nitinol. Patient has a body habitus that would inhibit X-ray visualization of the aorta Patient has a limited life expectancy of less than 1 year Patient is currently participating in another investigational device or drug clinical trial Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Nolte, MD
Organizational Affiliation
Herz- und Gefässzentrum Bad Bevensen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herz- und Gefässzentrum Bad Bevensen
City
Bad Bevensen
ZIP/Postal Code
29549
Country
Germany
Facility Name
Klinikum Dortmund GmbH
City
Dortmund
Country
Germany
Facility Name
Cardiovascular Center Frankfurt-Sankt Katherinen
City
Frankfurt
Country
Germany
Facility Name
Universitäres Herz und Gefäß Zentrum Hamburg
City
Hamburg
Country
Germany
Facility Name
Univeristy Klinik Köln
City
Köln
Country
Germany
Facility Name
Herzzentrum Leipzig
City
Leipzig
Country
Germany
Facility Name
St Franziskus Hospital Munster
City
Münster
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
23978572
Citation
Mehta M, Valdes FE, Nolte T, Mishkel GJ, Jordan WD, Gray B, Eskandari MK, Botti C; A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Ovation Abdominal Stent Graft System Investigators. One-year outcomes from an international study of the Ovation Abdominal Stent Graft System for endovascular aneurysm repair. J Vasc Surg. 2014 Jan;59(1):65-73.e1-3. doi: 10.1016/j.jvs.2013.06.065. Epub 2013 Aug 24.
Results Reference
derived

Learn more about this trial

TriVascular European Union (EU) Abdominal Stent Graft Trial

We'll reach out to this number within 24 hrs